Abstracts Archive - Page 209 of 2607 - ACR Meeting Abstracts

Abstract Number: PP16 • ACR Convergence 2024
Utilization of My Knee Notes for Enhanced Healthcare Management
Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA
Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
Abstract Number: PP13 • ACR Convergence 2024
Bridging the Gap from Pediatric to Adult Rheumatology Care
Natasha Trehan, University of Ottawa, Take a Pain Check Foundation, Markham, ON, Canada
Background/Purpose: When I was 13, life took an unexpected turn with a diagnosis of Juvenile Idiopathic Arthritis (JIA). Overnight, my world transformed into a cycle…
Abstract Number: 2646 • ACR Convergence 2024
Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries
Yosuke Kunishita¹, Urvashi Kaundal², Martin Kerick³, Ryan Routsong⁴, Justin Lack⁴, Ami Shah⁵, Maureen Mayes⁶, Daniel Shriner⁷, Ayo P. Doumatey⁷, Amy Bentley⁷, Robyn Domsic⁸, Thomas Medsger, Jr⁹, Paula Ramos¹⁰, Richard Silver¹¹, Virginia Steen¹², John Varga¹³, Vivien Hsu¹⁴, Lesley Ann Saketkoo¹⁵, Dinesh Khanna¹³, Elena Schiopu¹⁶, Jessica Gordon¹⁷, Lindsey Criswell¹⁸, Heather Gladue¹⁹, Chris Derk²⁰, Elana Bernstein²¹, S. Louis Bridges¹⁷, Victoria Shanmugam²², Lorinda Chung²³, Suzanne Kafaja²⁴, Reem Jan²⁵, Marcin Trojanowski²⁶, Avram Goldberg²⁷, Benjamin Korman²⁸, James W. Thomas²⁹, Elaine Remmers³⁰, Adebowale Adeyemo⁷, Charles Rotimi⁷, Fredrick Wigley³¹, Francesco Boin³², Javier Martin³, Daniel Kastner³³ and Pravitt Gourh³⁴, ¹Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, ³Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, ⁴Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁶UTHealth Houston Division of Rheumatology, Houston, TX, ⁷Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ¹²Georgetown University School of Medicine, Washington, DC, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹⁵New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹⁶Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁷Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁸Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²⁰Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²¹Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ²²Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, ²³Stanford University, Woodside, CA, ²⁴Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²⁵Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²⁶Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁷NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁸University of Rochester, Rochester, NY, ²⁹NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³⁰Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³¹Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ³²Cedars-Sinai Medical Center, Los Angeles, CA, ³³National Human Genome Research Institute, Bethesda, MD, ³⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…
Abstract Number: 2663 • ACR Convergence 2024
ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Monica Moreno, Shon Green, Kevin P. Nishimoto, Jackie Kennedy-Wilde, Taylor Barca, Melinda Au, Simona Costanzo, Gregory Vosganian, Benjamin Hsu, Francesco Galimi and Blake T. Aftab, Adicet Therapeutics, Inc., Redwood City, CA
Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…
Abstract Number: 2619 • ACR Convergence 2024
Safety Outcomes of Routine Blood Tests for Monitoring of Biologic and Targeted Synthetic Therapies in Inflammatory Arthritis Patients
Tali Eviatar¹, Iftach Sagy², Elad Brav², Amir Bieber³, Victoria Furer⁴ and Ori Elkayam⁵, ¹Tel Aviv Medical Center, Ramat Gan, HaMerkaz, Israel, ²Soroka Medical Cenrter, beer sheva, Israel, ³Emek Medical Center, Clalit Health Services, Raanana, Israel, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Patients treated with biologic or targeted synthetic (b/ts) DMARDs are recommended to perform safety blood monitoring every 3 months in the absence of strong…
Abstract Number: 2617 • ACR Convergence 2024
Higher Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures, Analysis of Data from 2020 – 2022
Emma Kersey¹, Jing Li², Julia Adler-Milstein³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s Rheumatology Informatics System for Effectiveness (RISE) web-based clinician dashboard enables quality performance monitoring and reporting in the Merit-Based Incentive…
Abstract Number: 2630 • ACR Convergence 2024
Identification of Molecular Biomarkers for Sjögren’s Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease
Aygalic Jara-Mikolajczak¹, Zachary Abessera¹, Martin Rethoret-Pasty¹, Elisa Mazuir¹, Apolline Bruley¹, Wan Fai Ng², Marta Alarcon-Riquelme³, Michele Bombardieri⁴, Simon Bowman⁵, Elena Pontarini⁶, Jacques-Eric Gottenberg⁷, Xavier Mariette⁸, Laurence LAIGLE⁹, Julien Duquesne¹, Philippe Moigeon¹⁰ and Vincent Bouget¹¹, and NECESSITY Consortium, ¹Scienta Lab, Paris, France, ²Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ³Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁴Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁵Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, ⁶William Harvey Research Institute, London, United Kingdom, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁹Servier Laboratories, France, SURESNES, France, ¹⁰Servier Laboratories, France, Gif sur Yvette, France, ¹¹Scienta Lab, Gif-sur-Yvette, France
Background/Purpose: Sjögren’s Disease (SjD) exhibits heterogeneity in clinical manifestations and underlying biology. This heterogeneity complicates drug development, with no targeted therapy approved to date. Identifying…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 2650 • ACR Convergence 2024
Extent of Vascular Inflammation on Cranial Vessel Wall MRI and Ophthalmic Complications in Giant Cell Arteritis
David Yang¹, Quy Cao², Fang Liu², Tara McWilliams², Ryan Rebello³, Madhura Tamhankar², Shubhasree Banerjee², Rui Liang², Robert Kurtz², Joshua Baker¹, Naomi Amudala², Zhaoyang Fan⁴, Jae Song², Peter Merkel¹, Jeffrey Morris² and Rennie Rhee¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³St Joseph’s Hospital and McMaster University, Hamilton, ON, Canada, ⁴University of Southern California, Los Angeles, CA
Background/Purpose: There is a need for measures of disease severity for giant cell arteritis (GCA), which may enable identification of high-risk subgroups (e.g., ophthalmic complications)…
Abstract Number: 2660 • ACR Convergence 2024
Developing Predictive Models for the Diagnosis of VEXAS Syndrome
Daniel Montes¹, Andrew C. Hanson², Hannah Langenfeld¹, Cynthia Crowson¹, Mrinal Patnaik¹, Ronald Go¹, Alexander Hines¹, Kambiz Kalantari¹, Yael Kusne³, Terra Lasho², Abhishek Mangaonkar¹, Horatiu Olteanu¹, Kaaren Reichard¹, Megan Sullivan⁴, David Viswanatha¹, Kenneth Warrington¹ and Matthew Koster¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Phoenix, AZ, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently identified autoinflammatory disorder with a heterogenous presentation. Patients may experience delays in diagnosis…
Abstract Number: 2662 • ACR Convergence 2024
In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Laurie Beitz¹, Maura Parker¹, Justin Ulrich-Lewis¹, Kristen Mittelsteadt¹, Rebecca Gottschalk¹, Chris Nicolai¹, Jim Qin¹, Andrew Scharenberg¹, Ryan Larson¹, Byoung Ryu¹, Eric Cavanaugh², Weiliang Tang¹, Seungjin Shin¹, Kelsey Lynch¹ and Hans-Peter Kiem², ¹Umoja Biopharma, Seattle, WA, ²Fred Hutch Cancer Research Center, Seattle, WA
Background/Purpose: CAR T cell therapy promises to revolutionize the treatment of hematologic malignancies, and more recently has generated early data that it may afford long…
Abstract Number: 2618 • ACR Convergence 2024
Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Danielle Bullock⁷, Jon Burnham⁸, Tzielan Lee⁹, Daniel Lovell¹⁰, Ted Wimmel¹¹, Delores Mincarelli¹¹, Mayur Patil¹², Magen Phillips¹¹ and Esi Morgan¹³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷M Health Fairview Masonic Children’s Hospital, Minneapolis, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Hive Networks, Newport, ¹²VSquare Infotech Inc, Edison, NJ, ¹³Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network with a vision that children with rheumatic disease will have…
Abstract Number: 2607 • ACR Convergence 2024
Clinical Outcomes and Costs of Care for Patients Within the Rheumatoid Arthritis Care Pathway Cohort at a Tertiary Care Integrated Delivery Network: A Comparison to Usual Care
Tarun Sharma¹, Tyson Barrett², Teigan Dwyer³, jessica heintzinger⁴, Ellen Kraemer¹, Sama Hajizadeh¹, paul lebovitz⁵, Adam Dore¹ and Susan Manzi¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Enterprise Data and Analytics, Highmark Health, Pittsburgh, ³Highmark Health, Pittsburgh, PA, ⁴Autoimmunity Institute, Pittsburgh, ⁵Medicine Institute, Pittsburgh
Background/Purpose: The RA care pathway initiative at Allegheny Health Network (AHN) was launched in collaboration with Highmark Health with the aim to improve clinical outcomes…
Abstract Number: 2450 • ACR Convergence 2024
Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
Eva Hoekstra¹, S. Ahmed², David Ueckert³, Nina Ajmone Marsan³, Philippine Kiès³, M.K. Ninaber³, Marlies Heuvers³, Miranda Geelhoed³, Thomas Huizinga⁴ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leids Universitair Medisch Centrum, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung…
Abstract Number: 2641 • ACR Convergence 2024
Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
Zhiyun Gong¹, Timothy Sullivan², Tammara Wood³, David Fox⁴, Dinesh Khanna⁵ and Michael Whitfield⁶, ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth, Hanover, NH, ⁴University of Michigan, Dexter, MI, ⁵University of Michigan, Ann Arbor, MI, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is molecularly heterogeneous and distinct subtypes of patients have been identified based on gene expression in skin. Although treatments have improved,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].